ALDX

Business Context and Reporting Period

Company: Aldeyra Therapeutics, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: March 10, 2023
Context: The filing addresses investor concerns regarding the company's exposure to Silicon Valley Bank following the bank's instability.

Key Financial Metrics

This filing does not contain financial statements, revenue, profit, cash flow, margin, debt, or liquidity metrics. The document is a regulatory disclosure regarding a specific banking relationship.

Material Changes

No material changes to financial performance or operations are reported in this document. The filing confirms the status of the company's banking relationships as of the report date.

Management Commentary and Risks

Regulation FD Disclosure (Item 7.01):

• The Company explicitly states it has no exposure to Silicon Valley Bank.
• Aldeyra does not hold cash deposits or securities with Silicon Valley Bank.
• The Company does not have any other business relationship with Silicon Valley Bank.

Legal Disclaimer: The information provided is furnished and not deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934 and shall not be incorporated by reference into other registration statements.

Investor Verification Checklist

• Verify the company's current cash and cash equivalents location in the most recent 10-Q or 10-K filing.
• Confirm the total amount of cash held by the company to assess overall liquidity independent of this specific disclosure.
• Review subsequent filings for any updates on banking relationships or liquidity events.